- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01716533
Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)
A Serological Study in Adult Subjects With Clostridium Difficile Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with an initial episode of CDI will be followed up for CDI recurrence or sustained clinical response. The subjects will be allocated into 2 groups at the study end:
- Recurrence Group: Subjects who experience recurrence of CDI after clinical response to antibiotic treatment to treat the initial CDI episode.
- Sustained response Group: Subjects who do not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
This protocol has been amended twice to improve recruitment of subjects in the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 1X5
- GSK Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- GSK Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol or/ and subjects who can receive assistance from his/ her legally acceptable representative (LAR) or a designate who can and will comply with the requirements of the protocol.
- A male or female aged 18 years or older at the time of enrolment.
- Written informed consent obtained from the subject/ LAR of the subject.
- A reasonable prognosis of survival during the study period as judged by the investigator.
- Outpatients, emergency room and/ or hospitalized subjects diagnosed with CDI for which the symptoms started maximum 14 days prior to study enrolment.
- Subjects who receive or plan to receive antibiotic treatment to treat the CDI episode.
Exclusion Criteria:
- Concurrently participating or planning to participate in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Previous CDI episode within the previous 6 months before study enrolment (except for up to ~25% of the subjects).
- Chronic diarrheal illness such as, but not limited to, ulcerative colitis or Crohn's disease.
- Planned surgery for CDI within 24 hours after study entry.
- Previous vaccination against Clostridium difficile.
- Having received a Clostridium difficile monoclonal antibody product(s) within the previous 3 months or planned administration during the study period.
- Administration of immunoglobulins within the previous 3 months or planned administration during the study period.
- Subject having any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject participating in the study, would make it unlikely for the subject to complete the study, or would confound the results of the study.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within the previous 6 months.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.
- Family history of congenital or hereditary immunodeficiency.
- Major congenital defects.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Recurrence group
Male or female subjects aged 18 years or older at the time of enrollment, who experienced recurrence of Clostridium difficile infection (CDI) after clinical response to antibiotic treatment to treat the initial CDI episode.
|
Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
|
OTHER: Sustained response group
Male or female subjects aged 18 years or older at the time of enrollment, who did not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
|
Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
|
OTHER: Failure to antibiotic Group
Male or female subjects aged 18 years or older at the time of enrollment, withdrawn due to failure of antibiotic treatment to treat the initial CDI episode.
|
Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
|
OTHER: Unclassified Group
Male or female subjects aged 18 years or older at the time of enrollment, who couldn't be classified as sustained response, recurrence, or failure to antibiotic due to missing data.
|
Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 14
Time Frame: At Day 14
|
Serum anti-toxin B antibody concentrations were expressed as Geometric Mean Concentrations (GMCs), as measured by the Enzyme Linked Immunosorbent Assay (ELISA) for the cut-off of equal to or above (≥) 100 EU/mL.
|
At Day 14
|
Serum F2 C-terminal Anti-toxin B Antibody Concentrations
Time Frame: At Day 14
|
Serum F2 C-terminal anti-toxin B antibody concentrations were expressed as Geometric Mean Concentrations (GMCs), as measured by ELISA for the cut-off of 13.16 EU/mL.
|
At Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 0 and Day 72
Time Frame: At Day 0 and at Day 72
|
Serum anti-toxin B antibody concentrations were expressed as Geometric Mean Concentrations (GMCs), as measured by ELISA for the cut-off equal to or above (≥) 100 EU/mL.
|
At Day 0 and at Day 72
|
Serum Neutralizing Anti-toxin A and Anti-toxin B Antibody Titers at Day 14
Time Frame: At Day 14
|
Neutralizing antibody concentrations were expressed as Geometric Mean Titers (GMTs), as measured in an inhibition of cytotoxicity assay (toxin neutralization assays) for the cut-off of 2, expressed in 1/DIL unit, in which DIL is the sample dilution corresponding to 50% neutralization.
|
At Day 14
|
Serum Neutralizing Anti-toxin A and Anti-toxin B Antibody Titers at Day 0, Within 10 Days After Recurrence and at Day 72
Time Frame: At Day 0, within 10 days after start of recurrent episode if any, and at end of follow-up (Day 72)
|
Neutralizing antibody concentrations were expressed as Geometric Mean Titers (GMTs), as measured in an inhibition of cytotoxicity assay (toxin neutralization assays) for the cut-off of 2, expressed in 1/DIL unit, in which DIL is the sample dilution corresponding to 50% neutralization.
This measure concerned only diarrhea recurrence.
No CDI recurrence was considered as part of the Group Sustained Response.
|
At Day 0, within 10 days after start of recurrent episode if any, and at end of follow-up (Day 72)
|
Number of Subjects With Clostridium Difficile Infection (CDI) Recurrence
Time Frame: From Day 0 to Day 72
|
A CDI recurrence is defined as the development of a new episode of CDI following clinical response at the end of standard of care (SoC) for the initial CDI episode.
|
From Day 0 to Day 72
|
CDI Initial Episodes Severity Characteristics, in All Subjects
Time Frame: At Day 0
|
Severity characteristics were expressed in duration of days for hospitalization, intensive care unit, Standard of Care (SoC) and CDI episodes.
|
At Day 0
|
Number of Subjects With Initial CDI Episode by Severity, in All Subjects
Time Frame: At Day 0
|
Initial CDI episodes were recorded by severity criteria: medical attention given, admission to intensive care unit, colectomy, death, high white blood cells (WBC) count, high creatinine count, hypotension/shock, clinical response to Standard of Care (SoC).
|
At Day 0
|
Number of Subjects With CDI Recurrence by Severity, in Those Subjects Who Recur
Time Frame: At recurrence (within 10 days of start diarrhea) during a follow up period of up to 72 days per participant
|
A CDI recurrence is defined as the development of a new episode of CDI following clinical response at the end of standard of care (SoC) for the initial CDI episode.
An episode of diarrhea was not considered as a recurrence of CDI if the stool was negative for C. difficile or if the diarrhea was attributed to another cause than C. difficile.
The severity criteria for CDI recurrent episodes were categorized into non-severe and severe.
|
At recurrence (within 10 days of start diarrhea) during a follow up period of up to 72 days per participant
|
Number of Subjects With Failure of Antibiotic Treatment
Time Frame: Within 3 months before the initial CDI episodes
|
Failure of antibiotic treatment against C. difficile is defined as the persistence or the incomplete resolution of symptoms (more than one unformed stool per day) after a full course of antibiotic(s) therapy (minimum 7 days). Aminopen+BetaLactam Inhib,1st Gen.Cephalosporin = Aminopenicillin+Beta-Lactamase Inhibitor and 1st Generation Cephalosporin. Aminopen+BetaLactam Inhib, 3rd Gen.Cephalosporin = Aminopenicillin+Beta-Lactamase Inhibitor and 3rd Generation Cephalosporin excluding Ceftazidime and Fluoroquinolone. Aminopen+BetaLactam Inhib and Fluoroquinolone = Aminopenicillin+Beta-Lactamase Inhibitor and Fluoroquinolone. Antipseudom Pen+BetaLactam Inhib and Cephalosporin = Antipseudomonal Penicillin+Beta-Lactamase Inhibitor and 1st Generation Cephalosporin and 3rd Generation Cephalosporin excluding Ceftazidime and Fluoroquinolone and Glycopeptides (Iv). Antipseudom Pen+BetaLactam Inhib and Glycopeptides = Antipseudomonal Penicillin+Beta-Lactamase Inhibitor and Glycopeptides (Iv). |
Within 3 months before the initial CDI episodes
|
Number of Subjects With Risk Factors Associated With the Initial CDI Episode
Time Frame: At Day 0
|
Risk factors for CDI included factors in three main domains involving host factors (advanced age, impaired immune status, co-morbidities); increased exposure to C. difficile spores (longer length of stays, healthcare environment, infected roommates or hand carriage by personnel); and factors that disrupt the normally protective colonic microflora layer (antimicrobials, other medications or procedures). CDI episodes within 6 months: Protocol exclusion criteria for enrolment allowed up to maximum 25% of the planned subjects having a previous CDI episode within the previous 6 months. Antibiotic taken within 3 months: Antibiotic not prescribed to treat C. difficile taken within 3 months before the current CDI episode. |
At Day 0
|
Number of Subjects With Risk Factors Associated With the CDI Recurrence
Time Frame: At recurrence (within 10 days of start diarrhea) during a follow up period of up to 72 days per participant
|
Risk factors for CDI included factors in three main domains involving host factors (advanced age, impaired immune status, co-morbidities); increased exposure to C. difficile spores (longer length of stays, healthcare environment, infected roommates or hand carriage by personnel); and factors that disrupt the normally protective colonic microflora layer (antimicrobials, other medications or procedures).
|
At recurrence (within 10 days of start diarrhea) during a follow up period of up to 72 days per participant
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116509
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Clostridium Difficile
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Hamilton Health Sciences CorporationRecruitingClostridium Difficile Diarrhea | Clostridium Difficile ColonizationCanada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
Microbiome Health Research InstituteBrown University; Tufts Medical Center; Indiana University; Edward HospitalTerminatedClostridium DifficileUnited States
-
Seres Therapeutics, Inc.Syneos HealthCompletedClostridium DifficileUnited States
-
University of AlbertaTerminatedClostridium DifficileCanada
-
McMaster UniversitySt. Joseph's Healthcare HamiltonTerminated
-
Astellas Pharma Europe Ltd.Merck Sharp & Dohme LLCCompletedClostridium DifficileGreece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
-
Assistance Publique - Hôpitaux de ParisRecruitingClostridium Difficile InfectionsFrance
Clinical Trials on Blood sampling
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
University Hospital, ToulouseCompletedPneumonia, PneumocystisFrance
-
Royal Surrey County Hospital NHS Foundation TrustCompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of ThyroidUnited Kingdom
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance